A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Information source: Endocyte
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Renal Cell Carcinoma
Intervention: EC90 (KLH-FITC) (Biological); GPI-0100 (Biological); EC17 (Folate-FITC) (Drug); Interleukin-2 (Drug); Interferon-alpha (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: Endocyte Official(s) and/or principal investigator(s): Richard A Messmann, MD, MHS, BSc, Study Director, Affiliation: Endocyte
Summary
This is a Phase 2 clinical trial to collect data on tumor responses produced by
folate-hapten conjugate therapy (vaccination with EC90 [KLH-FITC] and GPI-0100 adjuvant
followed by treatment with EC17 (folate-FITC) in combination with low-dose cytokines in
patients with progressive metastatic renal cell carcinoma. All patients will undergo imaging
with the investigational imaging agent 99mTc-EC20 (FolateScan) during the screening period
to confirm eligibility for the treatment portion of the clinical trial.
Clinical Details
Official title: A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Response Rate - the proportion of subjects with objective response based on RECIST criteria
Secondary outcome: To assess the safety and tolerability of folate-hapten conjugate therapyTime-to-progression, response duration, overall survival time observed after folate-hapten conjugate therapy and ECOG performance status To assess the safety and tolerability of 99mTc-EC20
Detailed description:
Rationale: This is a Phase 2 study of folate-hapten conjugate therapy in combination with
low-doses of the cytokines Interleukin-2 (IL-2) and Interferon-alpha (INF-alpha).
Folate-hapten conjugate treatment consists of subcutaneous vaccinations with EC90, a
compound designed to elicit an immune response (antibodies) to a dye called fluorescein
(FITC), in combination with GPI-0100 adjuvant (a drug intended to improve antibody
production). Vaccination is followed by treatment with EC17, a drug made by linking folate
(a vitamin) with FITC. Experimental evidence has shown that the folate receptor is
over-expressed in many human cancers, including renal cell carcinoma. It is expected that
EC17 will attach to cancer cells through the folate receptor and that antibodies to FITC
will recognize the cancer cell and mark it for destruction by the body's immune system. Two
drugs, IL-2 and IFN-alpha, will be administered at low doses in combination with EC17 in
order to boost the immune response. During the screening period, all potential patients
will undergo imaging with 99mTc-EC20 (a technetium-based, folate- linked radiopharmaceutical
[EC20]) for the purpose of identifying patients whose tumors express the folate receptor;
the target of folate-hapten conjugate therapy. Prior to receiving EC90/GPI-0100 and EC17
therapy, patients must exhibit at least one tumor lesion that displays adequate uptake of
99mTc-EC20 during the imaging procedure.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Must have a histologically confirmed diagnosis of renal cell carcinoma (clear cell or
predominately clear cell component). Papillary histology may also be enrolled
(maximum of 6 patients)
- Must be diagnosed with relapsed or Stage IV disease that is medically or surgically
unresectable and that has progressed after systemic therapy, including at least one
agent in the general class of kinase inhibitors (TKI not required for papillary
histology)
- Must have measurable/evaluable metastatic disease sites that have not previously
received radiotherapy and which does not require palliative intervention (at the time
of enrollment). Patients with non-measurable/evaluable disease are ineligible
- Must have at least one tumor lesion that displays uptake of 99mTc-EC20
- Must be > than or = 18 years of age
- Women must either be 1)not of child-bearing potential of 2)have a negative serum
pregnancy test within 7 days prior to commencing treatment with investigational
agents
- Must have completed prior cytotoxic chemotherapy, radiotherapy, immunotherapy or
experimental therapy 30 or more days prior to study enrollment, and recovered (or
returned to baseline) from associated acute toxicities. This restriction excludes
palliative radiotherapy.
- Must have an ECOG score less than or equal to 2
- Must have adequate hematologic, renal, and heptic function
Exclusion Criteria:
- Must not have a history of severe hypersensitivity (grade 3 - 4 allergic reaction) to
fluorescein, radiological contrast agent, cytokines, or have received fluorescein
within 30 days of the study
- Must not have medical conditions that preclude the use of IL-2 or IFN-α.
- Must not be pregnant or breast-feeding
- Must not be currently undergoing chemotherapy, anticancer hormonal therapy, and/or
therapy with immunosuppressant agents
- Must not be currently receiving bisphosphonates such as Zometa® (unless started >
four weeks prior to treatment with EC90/GPI-0100, in which case they can be
continued)
- Must not have any concomitant malignancy with the exception of basal cell or squamous
cell carcinoma of skin
- Must not have radiographically documented evidence of current brain metastases, a
history of stem cell transplant, immunodeficiency, and/or a medical or psychiatric
illness (that in the investigator's opinion, would prevent adequate compliance with
study therapy or evaluation of the endpoints)
- Must not have been administered another radiopharmaceutical that would interfere with
the assessment of 99mTc-EC20
- Must not be unable to tolerate conditions for radionuclide imaging
Locations and Contacts
University of Nebraska Medical Center, Omaha, Nebraska 68198-7680, United States
Hackensack University Medical Center, Hackensack, New Jersey 07601, United States
The Methodist Hospital Research Institute, Houston, Texas 77030, United States
Additional Information
Starting date: June 2007
Last updated: March 5, 2012
|